Skip to main content

KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

 

Aditxt, Inc. requests that their press release NewsItemId: 20250414955183 issued April 14, 2025 “Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials” be killed.

The release was issued in error by Aditxt, Inc.

A replacement release will not be issued at this time.

Contacts

Aditxt, Inc. 

Corporate Communications 

Jeff Ramson, PCG Advisory, Inc. 

T: 646-863-6893 

contactus@aditxt.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  208.69
+0.77 (0.37%)
AAPL  268.69
-4.26 (-1.56%)
AMD  200.51
-3.17 (-1.55%)
BAC  49.95
-2.35 (-4.49%)
GOOG  308.05
+0.90 (0.29%)
META  645.06
-11.95 (-1.82%)
MSFT  395.12
-6.60 (-1.64%)
NVDA  181.41
-3.48 (-1.88%)
ORCL  145.37
-4.94 (-3.29%)
TSLA  402.97
-5.61 (-1.37%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.